Argent Advisors, Inc. Affimed N.V. Transaction History

Argent Advisors, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2020 Apr 23, 2020	SELL	$1.44 - $3.02 $2,160 - $4,530	-1,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $3,375 - $4,605	1,500 New	1,500 $4,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Argent Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Argent Advisors, Inc. with notifications on news.